The precise chemical-physical nature of the pharmacore in FK506 binding protein inhibition: ElteX, a new class of nanomolar FKBP12 ligands

Journal of Medicinal Chemistry

Volumn 56, Issue 3, 2013, Pages 1041-1051

  Martina, Maria Raffaella ^a   Tenori, Eleonora ^a   Bizzarri, Marco ^a   Menichetti, Stefano ^a   Caminati, Gabriella ^a   Procacci, Piero ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ELTEX; FK 506 BINDING PROTEIN; PROTEIN INHIBITOR; UNCLASSIFIED DRUG;

AQUEOUS SOLUTION; ARTICLE; DIASTEREOISOMER; DRUG STRUCTURE; ISOMERIZATION; MOLECULAR DOCKING; PHYSICAL CHEMISTRY;

FLUORESCENCE; LIGANDS; MODELS, MOLECULAR; PIPERIDINES; PROTEIN BINDING; TACROLIMUS; TACROLIMUS BINDING PROTEIN 1A;

EID: 84873896713     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm3015052     Document Type: Article

References (57)

1. Blackburn, E. A.; Walkinshaw, M. D. Targeting FKBP isoforms with small-molecule ligands Curr. Opin. Pharmacol. 2011, 11, 365-371
2. Chattopadhaya, S.; Harikishore, A.; Yoon, H. S. Role of FK506 binding proteins in neurodegenerative disorders Curr. Med. Chem. 2011, 18, 5380-5397
3. Galat, A. Functional drift of sequence attributes in the FK506-binding proteins (FKBPs) J. Chem. Inf. Model. 2008, 48, 1118-1130
4. Gerard, M.; Deleersnijder, A.; Demeulemeester, J.; Debyser, Z.; Baekelandt, V. Unraveling the role of peptidyl-prolyl isomerases in neurodegeneration Mol. Neurobiol. 2011, 44, 13-27
5. Ivery, M. Immunophilins: switched on protein binding domains? Med. Res. Rev. 2000, 20, 452-484
6. Griffith, J.; Kim, J.; Kim, E.; Sintchak, M.; Thomson, J.; Fitzgibbon, M.; Fleming, M.; Caron, P.; Hsiao, K.; Navia, M. X-ray structure of calcineurin inhibited by the immunophilinimmunosuppressant FKBP12-FK506 complex Cell 1995, 82, 507-522
7. Rosen, M. K.; Schreiber, S. L. Natural-products as probes of cellular function-studies of immunophilins Angew. Chem., Int. Ed. Engl. 1992, 31, 384-400
8. Kissinger, C. R. Crystal-structures of human calcineurin and the human FKBP12-FK506-calcineurin complex Nature 1995, 378, 641-644
9. Liang, J.; Cho, i. J.; Clardy, J. Refined structure of the FKBP12-Rapamycin-FRB ternary complex at 2.2 A resolution Acta Crystallogr., Sect. D: Biol. Crystallogr. 1999, 55, 736-744
10. Banaszynski, L.; C.W., L.; Wandless, T. Characterization of the FKBP.rapamycin.FRB ternary complex J. Am. Chem. Soc. 2004, 127, 4715-4721
11. Waickman, A. T.; Powell, J. D. Mammalian target of rapamycin integrates diverse inputs to guide the outcome of antigen recognition in T cells J. Immunol. 2012, 188, 4721-4729
12. Kang, C.; Hong, Y.; Dhe-Paganon, S.; Yoon, H. FKBP family proteins: immunophilins with versatile biological functions Neurosignals 2008, 16, 318-325
13. Sugata, H.; Matsuo, K.; Nakagawa, T.; Takahashi, M.; Mukai, H.; Ono, Y.; Maeda, K.; Akiyama, H.; Kawamata, T. A peptidyl-prolyl isomerase, FKBP12, accumulates in Alzheimer neurofibrillary tangles Neurosci. Lett. 2006, 350, 472-477
14. Liu, F.; Liu, P.; Shao, H.; Kung, F. The intracellular domain of amyloid precursor protein interacts with FKBP12 Biochem. Biophys. Res. Commun. 2006, 350, 472-477
15. Gerard, M.; Deleersnijder, A.; Daniels, V.; Schreurs, S.; Munck, S.; Reumers, V.; Pottel, H.; Engelborghs, Y.; Van den Haute, C.; Taymans, J.; Debyser, Z.; Baekelandt, V. Inhibition of FK506 binding proteins reduces alpha-synuclein aggregation and Parkinson's disease-like pathology J. Neurosci. 2010, 30, 2454-2463
16. Esposito, M.; Ruffini, F.; Bellone, M.; Gagliani, N.; Battaglia, M.; Martino, G.; Furlan, R. Rapamycin inhibits relapsing experimental autoimmune encephalomyelitis by both effector and regulatory T cells modulation J. Neuroimmunol. 2010, 220, 52-63
17. Lisi, L.; Navarra, P.; Cirocchi, R.; Sharp, A.; Stigliano, E.; Feinstein, D. L.; Dello Russo, C. Rapamycin reduces clinical signs and neuropathic pain in a chronic model of experimental autoimmune encephalomyelitis J. Neuroimmunol. 2012, 243, 43-51
18. Lin, J. T.; Stein, E. A.; Wong, M. T.; Kalpathy, K. J.; Su, L. L.; Utz, P. J.; Robinson, W. H.; Fathnnan, C. G. Differential mTOR and ERK pathway utilization by effector CD4 T cells suggests combinatorial drug therapy of arthritis Clin. Immunol. 2012, 142, 127-138
19. Manabe, Y.; Warita, H.; Murakami, T.; Shiote, M.; Hayashi, T.; Omori, N.; Nagano, I.; Shoji, M.; Abe, K. Early decrease of the immunophilin FKBP 52 in the spinal cord of a transgenic model for amyotrophic lateral sclerosis Brain Res. 2002, 935, 124-128
20. Benjamin, D.; Colombi, M.; Moroni, C.; Hall, M. N. Rapamycin passes the torch: a new generation of mTOR inhibitors Nature 2011, 10, 868-880
21. Gerard, M.; Debyser, Z.; Desender, L.; Kahle, P. J.; Baert, J.; Baekelandt, V.; Engelborghs, Y. The aggregation of alpha-synuclein is stimulated by FK506 binding proteins as shown by fluorescence correlation spectroscopy FASEB J 2006, 20, 524-526
22. Roehrig, C. H.; Loch, C.; Guan, J.-Y.; Siegal, G.; Overhand, M. Fragment-Based Synthesis and SAR of Modified FKBP Ligands: Influence of Different Linking on Binding Affinity Chem. Med. Chem. 2007, 2, 1054-1070
23. Bizzarri, M.; Marsili, S.; Procacci, P. Intraligand hydrophobic interactions rationalize drug affinities for peptidyl-prolyl cis-trans isomerase protein J. Phys. Chem. B 2011, 115, 6193-6201
24. Holt, D. A.; Luengo, J. J. I.; Yamashita, D. S.; Oh, H. J.; Konialian, A. L.; Yen, H. K.; Rozamus, L. W.; Brandt, M.; Bossard, M. J.; Levy, M. A.; Eggleston, D. S.; Liang, J.; Schultz, L. W.; Stout, T. J.; Clardyt, J. Design, synthesis, and kinetic evaluation of high-affinity FKBP ligands and the X-ray crystal structures of their complexes with FKBP 12 J. Am. Chem. Soc. 1993, 115, 9925-9938
25. Holt, D. A.; Konialian-Beck, A. L.; Oh, H. J.; Yen, H. K.; Rozamus, L. W.; Krog, A. J.; Erhard, K. F.; Ortiz, E.; Levy, M. A.; Brandt, M.; Bossard, M. J.; Luengo, J. I. Structureactivity studies of synthetic FKBP ligands as peptidyl-prolyl isomerase inhibitors Bioorg. Med. Chem. Lett. 1994, 4, 315-320
26. Hamilton, G. S.; Catonsville, M.; Snyder, S.; Baltimore, M. Inhibitors of rotamase enzyme activity effective at stimulating neuronal growth. U.S. Patent 5696135, 1997.
27. Van-Duyne, G.; Standaert, R. F.; Schreiber, S. L.; Clardy, J. Atomic structure of the rapamycin human immunophilin FKBP-12 complex J. Am. Chem. Soc. 1991, 113, 7433-7434
28. Kotaka, M.; Ye, H.; Alag, R.; Hu, G.; Bozdech, Z.; Preiser, P.; Yoon, H.; Lescar, J. Crystal structure of the FK506 binding domain of Plasmodium falciparum FKBP35 in complex with FK506 Biochemistry 2008, 47, 5951-5961
29. Alag, R.; Qureshi, I.; Bharatham, N.; Shin, J.; Lescar, J.; Yoon, H. S. NMR and crystallographic structures of the FK506 binding domain of human malarial parasite Plasmodium vivax FKBP35 Protein Sci. 2010, 19, 1577-1586
30. Gopalakrishnan, R.; Kozany, C.; Gaali, S.; Kress, C.; Hoogeland, B.; Bracher, A.; Hausch, F. Evaluation of synthetic FK506 analogues as ligands for the FK506-binding proteins 51 and 52 J. Med. Chem. 2012, 55, 4114-4122
31. Wallace, A. C.; Laskowski, R. A.; Thornton, J. M. LIGPLOT: A program to generate schematic diagrams of protein-ligand interactions Protein Eng. 1995, 8, 127-134
32. Bizzarri, M.; Tenori, E.; Martina, M. R.; Marsili, S.; Caminati, G.; Menichetti, S.; Procacci, P. New perspective on how and why immunophilin FK506-related ligands work J. Phys. Chem. Lett. 2011, 2, 2834-2839
33. Armistead, D. M.; Badia, M. C.; Deininger, D. D.; Duffy, J. P.; Saunders, J. O.; Tung, R. D.; Thomson, J. A.; Decenzo, M. T.; Futer, O.; Livingston, D. J.; Murcko, M. A.; Yamashitaand, M. M.; Navia, M. A. Design, synthesis and structure of non-macrocyclic Inhibitors of FKBPI2, the major binding protein for the immunosuppressant FKS06 Acta Crystallogr. 1995, D51, 522-528
34. Park, S. T.; Aldape, R. A.; OlgaFuter; DeCenzo, M. T.; Livingston, D. J. PPIase catalysis by human FK506-binding protein proceeds through a conformational twist mechanism J. Biol. Chem. 1992, 267, 3316-3324
35. Fukunishi, H.; Watanabe, O.; Takada, S. On the Hamiltonian replica exchange method for efficient sampling of biomolecular systems: Application to protein structure prediction J. Chem. Phys. 2002, 116, 9058-9067
36. Marsili, S.; Signorini, G. F.; Chelli, R.; Marchi, M.; Procacci, P. ORAC: A molecular dynamics simulation program to explore free energy surfaces in biomolecular systems at the atomistic level J. Comput. Chem. 2010, 31, 1106-11161
37. Liu, P.; Kim, B.; Friesner, R. A.; Berne, B. J. Replica exchange with solute tempering: A method for sampling biological systems in explicit water Proc. Acad. Sci. 2005, 102, 13749-13754
38. Duan, Y.; Wu, C.; Chowdhury, S.; Lee, M. C.; Xiong, G.; Zhang, W.; Yang, R.; Cieplak, P.; Luo, R.; Lee, T.; Caldwell, J.; Wang, J.; Kollman, P. A point-charge force field for molecular mechanics simulations of proteins based on condensed-phase quantum mechanical calculations J. Comput. Chem. 2003, 24, 1999-2012
39. Stephens, P. J.; Devlin, F. J.; Chablowski, C. F.; Frisch, M. Ab initio calculation of vibrational absorption and circular dichroism spectra using density functional force fields J. Phys. Chem. 1994, 98, 11623-11627
40. Singh, U. C.; Kollman, P. A. An approach to computing electrostatic charges for molecules J. Comput. Chem. 1984, 5, 129-145
41. Heyer, L. J.; Kruglyak, S.; Yooseph, S. Exploring expression data: identification and analysis of coexpressed genes Genome Res. 1999, 9, 1106-1115
42. Guardiani, C.; Signorini, G. F.; Livi, R.; Papini, A. M.; Procacci, P. Conformational landscape of N-glycosylated peptides detecting autoantibodies in multiple sclerosis, revealed by hamiltonian replica exchange J. Phys. Chem. B 2012, 116, 5458-5467
43. Brown, H. C.; Jadhavl, K. J. Asymmetric carbon-carbon bond formation via β-allyldiisopinocampheylborane. Simple synthesis of secondary homoallylic alcohols with excellent enantiomeric purities J. Am. Chem. Soc. 1983, 105, 2092-2093
44. Sun, F.; Li, P.; Ding, Y.; Wang, L.; Bartlam, M.; Shu, C.; Shen, B.; Jiang, H.; Li, S.; Rao, Z. Design and structure-based study of new potential FKBP12 inhibitors Biophys. J. 2003, 85, 3194-3201
45. The conformations of sb3 diastereoisomers in water were obtained using the trajectory data of a previous work: Bizzarri, M. J. Phys. Chem. B 2011, 115, 6193-6201
46. i relative to FK506 were taken from Holt, D. A. J. Am. Chem. Soc. 1993, 115, 9925-9938
47. i relative to FK506 were taken from Armistead, D. M. Acta Crystallogr. 1995, D51, 522-529
48. Williams, T.; Kelley, C. Gnuplot 4.4, An Interative Plotting Program. 2011; http://sourceforge.net/projects/gnuplot.
49. Procacci, P. Thermodynamics of stacking in proteins Annu. Rep. Progr. Chem. Sect. C 2011, 107, 242-262
50. Hummer, G. Molecular binding: Under water's influence Nature Chem. 2010, 2, 906-906
51. Wand, X.; Etzkorn, F. Peptidyl-prolyl isomerase inhibitors Biopolymers 2006, 84, 125-146
52. Harding, M.; Galat, A.; Uehling, D.; Schreiber, S. A receptor for the immunosuppressant FK506 is a cis-trans peptidyl-prolyl isomerase Nature 1989, 341, 758-760
53. Siekierka, J.; Hung, S.; Poe, M.; Lin, C.; Sigal, N. A cytosolic binding protein for the immunosuppressant FK 506 has peptidyl-prolyl isomerase activity but is distinct from cyclophilin Nature 1989, 341, 755-757
54. Fischer, S.; Michnick, S.; Karplus, M. A mechanism for rotamase catalysis by the FK506 binding protein (FKBP) Biochemistry 1993, 32, 13830-13837
55. Gambinossi, F.; Lorenzelli, L.; Baglioni, P.; Caminati, G. Silicon oxide surface functionalization by self-assembled nanolayers for microcantilever transducers Colloids Surf. A Physicochem. Eng. Asp. 2008, 321, 87-93
56. Morandi, S.; Puggelli, M.; Caminati, G. Antibiotic association with phospholipid nanoassemblies: A comparison between Langmuir-Blodgett films and supported lipid bilayers Colloids Surf., A 2008, 321, 125-130
57. Al-Kayal, T.; Russo, E.; Pieri, L.; Caminati, G.; Berti, D.; Bucciantini, M.; Stefani, M.; Baglioni, P. Interactions of lysozyme with phospholipid vesicles: effects of vesicle biophysical features on protein misfolding and aggregation Soft Matter 2012, 8, 9115-9126